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Abstract
Background Atypical haemolytic uremic syndrome (aHUS)
is often associated with a high risk of disease recurrence and
subsequent graft loss after isolated renal transplantation.
Evidence-based recommendations for a mutation-based
management after renal transplantation in aHUS caused by
a combined mutation with complement factor I (CFI) and
membrane cofactor protein CD46 (MCP) are limited.
Case-diagnosis/Treatment We describe a 9-year-old boy
with a first manifestation of aHUS at the age of 9 months
carrying combined heterozygous mutations in the CFI and
MCP genes. At the age of 5 years, he underwent isolated
cadaveric renal transplantation. Fresh frozen plasma was
administered during and after transplantation, tapered and
finally stopped after 3 years.
Conclusions During the 5-year follow-up after transplanta-
tion there have been no signs of aHUS recurrence and graft
function has remained good. The combination of heterozy-
gous MCP and CFI mutations with aHUS might have a
positive impact on the post-transplant course, possibly
predicting a lower risk of aHUS recurrence after an isolated
cadaveric renal transplantation
Introduction
Atypical haemolytic uremic syndrome (aHUS) has a high rate
of disease recurrence after renal transplantation [1, 2], with the
recurrence dependent on the mutated gene(s) involved in the
pathogenetic mechanism. Mutations in membrane cofactor
protein CD46 (MCP) are associated with a lower recurrence
rate and better renal graft function than mutations in circulat-
ing regulators of the complement system, such as complement
factor H (CFH) or complement factor I (CFI) [3–5]. Although
patients carrying two or more mutations have been described
[1], evidence for the management of renal transplantation in
patients with aHUS caused by combined CFI/MCP mutations
is still limited [4]. Here, we describe a 9-year-old boy suffer-
ing from aHUS carrying heterozygous mutations of both CFI
and MCP with a favourable 5-year follow-up after isolated
cadaveric renal transplantation without aHUS recurrence and
good graft function.
Case report
The boy was born with congenital neuroblastoma with spon-
taneous regression by the age of 7 months. At the age at
9 months anaemia, thrombocytopenia and renal insufficiency
led to the diagnosis of aHUS. As these symptoms arose with
fever and otitis media, Streptococcus pneumoniae-associated
HUS was initially suggested and plasmatherapy was not
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administered. Peritoneal dialysis was initiated at the age of
10 months due to progressive renal failure. After an initial
improvement of both renal function and thrombocytopenia, a
first relapse of the aHUS at the age of 11 months led to end
stage renal disease (ESRD).
Genetic analysis revealed heterozygous splice site muta-
tion of theMCP gene (IVS2-2A>G) [6]. This mutation leads
to the skipping of exon 3 causing the loss of amino acids
62–95 with a 3-amino acid change and protein interruption
at L99 [5, 6]. The same mutation was found in the healthy
father. A previously published functional analysis of IVS2-
2A>G demonstrated that heterozygous patients express
50 % of the normal MCP level [5]. Our patient also carried
the aHUS MCPggaac risk haplotype [7] since he was het-
erozygous for the c.2232T>C polymorphism. The genetic
analysis also revealed a heterozygous 5-bp deletion of CFI,
delTTCAC(1446–1450), in the boy and the healthy mother;
this deletion causes a frameshift and introduction of a pre-
mature stop codon (W486Stop) [6], resulting in an abnormal
protein that is not secreted [8]. The CFI levels measured in
the serum of our patient were consistently at the lower range
(77 %; normal range 70–130 %) [6]. The genetic screening
of thrombomodulin, CFH as well as the levels of CFH were
normal. However, the patient was also heterozygous for the
−257 T, 2,089 G and 2,881 T CFH polymorphisms targeting
the aHUS disease risk haplotype H3 [9]. Homozygous de-
letion of CFHR1-R3 and autoantibodies to CFH were ex-
cluded. Genetic screening for C3, CFB and CFHR5 was not
performed.
At the age of 5 years, the patient underwent isolated ca-
daveric renal transplantation with two donor-HLA-matches.
Fresh frozen plasma (FFP; i.e.Octaplas®; Octapharma Plas-
ma,Charlotte, NC ) (20 ml/kg) was administered immediately
before and after transplantation, followed by daily doses for
19 days and then a gradual tapering of the FFP infusions—
three times a week for 2 weeks, twice a week for 7 weeks,
once a week for 8 weeks, once every other week for 4 months,
once every 3 weeks for 3 months and once every 4 weeks for
1 year. Two years after transplantation, FFP infusions were
given once every 2 months for a further year and finally
stopped 3 years after transplantation. Initial immunosuppres-
sion therapy consisted of cyclosporine A (10 mg/kg/day),
mycophenolate mofetil (1,200 mg/m2/day) and prednisolone
(2 mg/kg/day) and resulted in good primary renal graft func-
tion. Eleven days after transplantation, cyclosporine A was
switched to tacrolimus (0.4 mg/kg/day, aiming at a trough
level of approx. 10–15 μg/l for 4 weeks, 3–7 μg/l thereafter)
and intravenous methylprednisolone was administered
(500 mg/m2 once daily for 6 days) based on a biopsy-proven
cellular graft rejection (Banff IIA). Volume overload required
transient hemofiltration; in addition, one single plasma
exchange was performed with FFP (40 ml/kg) as a preventive
measure. Consistent with the benign clinical course, renal
biopsy showed no evidence of thrombotic microangiopathy.
Twenty-nine days after transplantation, a second graft
rejection was diagnosed on renal biopsy (Banff IIB)
and the patient was treated again with 4 doses of daily
intravenous methylprednisolone. Renal protocol biopsy
6 months after transplantation was normal without evi-
dence of thrombotic microangiopathy (TMA) or comple-
ment deposition. No complement depositions were seen
in the previous two biopsies.
After transplantation, the patient suffered from several
viral and bacterial infections, including esophagitis (human
herpesvirus type 1), enteritis (Clostridium difficile toxin),
reactivation of cytomegalovirus, viral meningitis and uri-
nary tract infections. These were treated with the appropriate
antiviral or antimicrobial drugs, but without intensifying
FFP administration.
Neither clinical nor laboratory signs of aHUS recurrence
appeared during the 5-year follow-up after transplantation with
maintenance of a good glomerular renal function (Table 1),
normal blood pressure and no proteinuria. Additionally, the
child’s general development and growth are normal (within the
10th and 25th centile).
Discussion
We describe a 9-year-old boy (current age) suffering from
aHUS who carries combined heterozygous mutations in the
MCP and CFI genes. He presented with the first episode of
aHUS at the age of 9 months followed by a first relapse at
11 months that led to ESRD. Genetic analysis revealed that
the boy had inherited the MCP and CFI mutations from his
healthy father and mother, respectively [6]. This observation
suggests that these specific mutations on the MCP and the
CFI gene do not necessarily lead to aHUS if present as a
single, isolated mutation. It is possible, however, that the
combination of any trigger (e.g. infection, but often un-
known) with the presence of a heterozygous mutation (e.g.
that of the parents) might result in aHUS.
The performance of an isolated transplantation was con-
troversial as, at that time, no data were available on patients
with combined heterozygous MCP/CFI mutations. The
presence of the CFI mutation in our patient would have
argued against an isolated transplantation, as graft failure
due to aHUS recurrence had been reported in patients with
heterozygous CFI mutations [10, 11]. The difficult course of
the patient, the unknown risk of a combined liver–kidney
transplantation, the lack of specific antibodies against com-
plement proteins at that time (e.g. eculizumab) and the re-
duced long-term life expectancy on dialysis finally led to the
decision to perform an isolated renal transplantation. Both
parents were excluded as potential donors, based on the in-
creased risk of developing aHUS relapse in the recipient and
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the devastating possibility of triggering aHUS in the hetero-
zygous donor by removing one kidney [12].
To our knowledge, only one case report has described a
successful isolated renal transplantation in a patient with
aHUS carrying mutations in both CFI and MCP—in this
case, a 36-year-old man [13]. The patient received daily FFP
infusions during the first 10 days after transplantation.
Follow-up 9 months after transplantation showed acute hu-
moral graft rejection, but no aHUS recurrence.
Kidney graft outcome seems to be favourable in patients
with isolated MCP mutations without disease recurrence in
the renal graft, taking into account that MCP is a transmem-
brane protein highly expressed in the kidney [14]. Normal
MCP in the kidney graft may have prevented the recurrence
of aHUS in our patient as multiple hits in complement genes
are involved in the pathogenesis of aHUS, as reported by
Cruzado et al. [13]. However, Frémeaux-Bacchi et al.
reported that vascular microchimerism, in which the mutat-
ed protein is produced in the kidney graft by endothelial
cells originating from the recipient, may favour aHUS re-
currence [15].
In our patient, measures to prevent recurrent aHUS after
transplantation included the administration of FFP and one
session of plasma exchange. We observed neither clinical
nor laboratory signs of aHUS recurrence despite multiple
potential triggers, such as repeated graft rejection and mul-
tiple infections necessitating pharmacologic treatment. Even
2 years after stopping FFP infusions, no aHUS recurrence
occurred. The frequency of FFP administration was chosen
empirically due to lack of data on aHUS patients with a
combined MCP/CFI mutation. The half life of CFI is about
29–45 h. Effective levels of CFI have been maintained after
a single infusion of 27–40 ml/kg FFP in homozygous CFI-
deficient patients for 8 days, and the effects on C3d/C4d
formation have lasted up to a maximum of 16 days [16]. In
addition, it cannot be excluded that there are other mutations
in circulating complement proteins not yet defined. The fact
that the above-mentioned patient with combined CFI/MCP
mutations [13] required only 10 days FFP treatment may
suggest that a shorter treatment time with FFP in our patient
could also have been sufficient.
Other combinations ofmutations in complement regulatory
genes with different outcomes after renal transplantation have
been reported [3, 17–19]. Seitz et al. [17] described adult
patients, two with combined MCP/CFH mutations and one
with three mutations involving MCP, CFH and CFI; all de-
veloped aHUS recurrence after transplantation, and two suc-
cessfully treated with plasma exchange. Sellier–Leclerc et al.
[3] reported one child carrying mutations in both CFH and
CFI with no aHUS recurrence after renal transplantation dur-
ing a 3 year-follow-up.
Although a favourable course has been observed in our
patient to date, the risk of aHUS recurrence may still remain
due to potential exposure to unknown environmental trig-
gers in combination with this specific genetic background
[20].
Regular screening for signs of haemolysis and the imme-
diate initiation of the appropriate treatment when required
are indispensable in the case of aHUS recurrence (e.g.
plasma exchange/infusion, complement blockers). The cur-
rently available complement blockers (e.g. eculizumab) may
reduce the risk of aHUS recurrence in renal transplant
without the need of long-term plasma therapy. This may be
relevant if only isolated renal transplantation is performed,
such as in a patient with aHUS with a combined CFI/MCP
mutation, where the underlying CFI mutation carries a high
risk for a poor outcome, including graft loss [10]. However,
the combination of heterozygous MCP and CFI mutations
with aHUS may also predict a lower risk of aHUS recurrence
after an isolated renal transplantation.
Table 1 Post-transplant course of haemolysis parameters and plasma creatinine
Haemolysis parameters
and plasma creatinine
Day of
transplantation
Days/months/years after transplantation
Day 2 Day 9 Day 28 Month 5 Month 12 3 years 5 years
Platelets (G/l) 214 255 464 338 505 510 223 317
Hematocrit (l/l) 0.27 0.33 0.25 0.24 0.27 0.34 0.33 0.41
Lactate
dehydrogenase (U/l)
201 250 351 195 274 255 205 194
Schistocytes None None None None None None None None
Creatinine (μmol/l) 950 66 146 82 81 65 45 49a
Biopsy – – Banff IIA rejection
No TMA
Banff IIB rejection
No TMA
Normal biopsy
No TMA
– –
Fresh frozen
plasma infusion
Daily Daily Daily Three times a week Every 2 weeks Monthly – –
TMA, Thrombotic microangiopathy
a Normal range for plasmatic creatinine: <60 μmol/l. Estimated glomerular filtration rate by the Schwartz formula with k = 0.4: 80 ml/min/1.73 m2
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